Radio-chemo-immunotherapy (CCNU plus levamisole) for treatment of metastatic brain tumors. A pilot study.
Thirty-one patients with metastatic brain tumors were treated with Radiotherapy (RT) and CCNU or with RT, CCNU and Levamisole (LMS) in a randomized clinical trial. Twenty-seven were evaluable. All patients were submitted to whole brain radiation (50 +/- 5 Gy) and CCNU (130 mg/m2 p.o. every 8 weeks). 15 also received Levamisole (2.5 mg/kg p.o. daily for 3 weeks in the first month, for 2 weeks in the second, and then once a week monthly until progression). Primary tumor was predominantly lung cancer (22/27) and brain lesions were generally multiple (24/27). The overall response rate was 35% in the RT plus CCNU treated group and 38% in the RT plus CCNU plus LMS treated group. The median survival time was similar and not statistically different in both groups (7 versus 6 months). No important side effects were observed either in the RT + CCNU or in the RT + CCNU + LMS treated groups. The absence of combined depression of T-cell levels and responsiveness of lymphocytes to mitogens suggests that thymus dependent immunity could be improved by LMS administration. However, such improvement had no impact on duration of survival in patients with metastatic brain tumors.
D000971:Antineoplastic Combined Chemotherapy Protocols; D001932:Brain Neoplasms / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007978:Levamisole / Q000008:administration & dosage*; D008130:Lomustine / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000628:therapy; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology
D007136:Immunoglobulins; D007978:Levamisole; D008130:Lomustine